Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s

Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks.

With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion in revenue from emerging businesses by the mid-2030s.

Merck & Co., Inc. (NYSE:MRK) expects cardiometabolic and respiratory treatments to generate $20 billion, up from a prior forecast of $15 billion. Meanwhile, infectious disease drugs are projected at $15 billion, compared with $5 billion previously. The increase in expectations reflects accelerated launch plans and an expanding late-stage pipeline that has nearly tripled since 2021, including acquisitions like Acceleron.

The accelerated momentum was showcased earlier on January 8, 2026, when Reuters reported that Merck & Co., Inc. (NYSE:MRK) is working toward a $28-32 billion acquisition of Revolution Medicines, a deal not yet finalized. The deal, which could be the largest in nearly three years, is expected to add over $10 billion in risk-adjusted global sales by 2035. With this move, the company aims to offset patent expirations and strengthen its oncology pipeline.

Merck & Co., Inc. (NYSE:MRK), a healthcare provider, offers pharmaceutical, vaccines, biologics, and animal health products. The company focuses on innovation, pipeline expansion, and therapies for human and animal disease management worldwide.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.